Anika Therapeutics | ANIK - SCHULD





SCHULD Veränderung Datum
Abbott USD 34.05B 20.19B 2026-03
Agenus USD 35.54M 2.34M 2025-03
Agios Pharmaceuticals USD 35.74M 4.46M 2026-03
Anika Therapeutics USD 0 0 2025-03
Arrowhead Research USD 983.69M 5.77M 2026-06
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Heron Therapeutics USD 149.65M 157K 2024-09
Insmed USD 725.8M 1.82M 2026-06
Integra LifeSciences USD 2.04B 6.27M 2026-03
Intrexon USD 0 13.82M 2024-06
J&J USD 49.04B 5.95B 2026-06
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
Ligand Pharmaceuticals USD 451.98M 486K 2026-03
MacroGenics USD 36.51M 500K 2026-03
Merit Medical Systems USD 821.56M 9K 2026-03
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 23.58B 3.56B 2026-06
Stryker USD 14.19B 32M 2026-06
Veracyte USD 39.33M 321K 2026-03
Xencor USD 175.16M 12.58M 2026-03
Zimmer Biomet Holdings USD 7.48B 8M 2026-06